Ce que va changer le traitement contre le cancer Sarclisa, approuvé par l’UE pour la première fois
The European Commission has granted marketing authorization for a subcutaneous formulation of Sarclisa (isatuximab), a significant development for patients diagnosed with multiple myeloma. This regulatory decision marks the first time a subcutaneous version of this monoclonal antibody has been approved for use within the European Union, offering a potentially more flexible administration process compared to … Read more
